

1 **Title: Real World Effectiveness of Tixagevimab/cilgavimab (Evusheld) in the**
2 **Omicron Era**

3
4 **Short title: COVID-19 among Immunocompromised Patients Before and After**
5 **Tixagevimab/cilgavimab**

6
7
8
9 Benjamin Chen*, MD, MPH, Department of Medicine, Infectious Diseases and Global
10 Public Health, University of California, San Diego

11
12 Nina Haste*, PharmD PhD, Department of Pharmacy, University of California, San
13 Diego

14
15 Nancy Binkin, MD, MPH, The Herbert Wertheim School of Public Health and Human
16 Longevity University of California, San Diego

17
18 Nancy Law, DO, MPH, Department of Medicine, Infectious Diseases and Global Public
19 Health, University of California, San Diego

20
21 Lucy E. Horton, MD, MPH, Department of Medicine, Infectious Diseases and Global
22 Public Health, University of California, San Diego

23
24 Nancy Yam, PharmD, Department of Pharmacy, University of California, San Diego

25
26 Victor Chen, PharmD, Department of Pharmacy, University of California, San Diego

27
28 Shira Abeles, MD, Department of Medicine, Infectious Diseases and Global Public
29 Health, University of California, San Diego

30
31
32 Corresponding Author: Shira Abeles, MD
33 9500 Gilman Drive MC 0507
34 La Jolla, CA 92093-0507
35 sabeles@health.ucsd.edu

36
37
38 Manuscript Word Count: 2,337

39
40

41 **Abstract:**

42

43 **Background:** Pre-exposure prophylaxis for COVID-19 with tixagevimab/cilgavimab

44 (T/C) received Emergency Use Authorization (EUA) based off of results from a clinical

45 trial conducted prior to the Omicron variant. Its clinical effectiveness has not been well

46 described in the Omicron era. We examined the incidence of symptomatic illness and

47 hospitalizations among T/C recipients when Omicron accounted for virtually all cases.

48

49 **Methods:** We used the electronic medical record to identify patients who received T/C

50 at our institution. Among these patients, we assessed for cases of symptomatic

51 COVID-19 and associated hospitalizations before and after receiving T/C. We used chi

52 square tests and Fishers exact p-values to examine differences between characteristics

53 of those who got COVID before and after T/C prophylaxis.

54

55 **Results:** Of 1295 T/C recipients, 121 (9.3%) developed symptomatic COVID-19 before

56 receiving T/C, and 102 (7.9%) developed symptomatic disease after receiving it. Among

57 those with infection prior to T/C, 36/121 (29.8%) were hospitalized, including 8 (6.6%)

58 admitted to the ICU. Among those with COVID-19 after receiving T/C, 6/102 (5.9%)

59 were hospitalized but none required ICU admission. No COVID-related deaths occurred

60 in either group. The majority of COVID-19 cases among those infected prior to T/C

61 treatment occurred during Omicron BA.1 surge, while the majority of cases among post-

62 T/C recipients occurred when BA.5 was predominant. Patients infected with COVID-19

63 prior to receiving T/C had received fewer vaccine doses and were less likely to receive

64 COVID-19 therapeutics compared to those with COVID-19 after having received T/C.

65

66 **Conclusion:** We identified COVID-19 infections after T/C prophylaxis. Among persons
67 eligible for T/C, COVID-19 illnesses occurring after T/C were less likely to require
68 hospitalization compared to those with COVID-19 prior to T/C. In the presence of
69 changing vaccine coverage, multiple therapies, and changing variants, the effectiveness
70 of T/C in the Omicron era remains difficult to assess.

71

72

73

74

75

76 **Introduction**

77 COVID-19 vaccines have dramatically reduced the severity of disease caused by
78 SARS-CoV-2 infection.¹ Immunocompromised patients, however, remain at risk for
79 SARS-CoV-2 infections and, if infected, an increased risk of severe illness,
80 hospitalization, and death. Although the overall mortality in immunocompromised
81 patients with the SARS-CoV-2 Omicron variant has been shown to be lower than with
82 prior variants, studies have shown that hospitalization and prolonged duration of
83 symptoms have remained high for this vulnerable population.²

84 Tixagevimab/cilgavimab (AZD7442; Evusheld, subsequently referred to as T/C), which
85 consists of AZD8895 and AZD1061 (AstraZeneca), two long-acting monoclonal
86 antibodies, was shown in the PROVENT trial to reduce the risk of symptomatic COVID-
87 19 infection by 83% compared with placebo.³ In early December 2021, the Food and
88 Drug Administration (FDA) granted an Emergency Use Authorization (EUA) of T/C for
89 pre-exposure prophylaxis for moderately to severely immunocompromised adults and
90 adolescents, and for those not eligible for COVID-19 vaccination due to a history of a
91 severe reaction.

92 The authorization of T/C coincided with the emergence of the Omicron variant, which
93 resulted in previously effective monoclonal antibodies losing effectiveness.^{4 5 6 7} There
94 is limited data available on the real-world effectiveness of T/C, especially in the Omicron
95 era. T/C requires significant resources for administration due to its EUA status and
96 associated institutional requirements for administering it. We therefore investigated
97 COVID-19 infections and clinical outcomes in a cohort of immunocompromised patients

98 who received T/C for pre-exposure prophylaxis within a single health system during a
99 period when Omicron was the predominant circulating variant.

100 **Methods**

101 The study was conducted at the University of California San Diego’s Health System (UC
102 San Diego Health), a quaternary referral center serving a large population with many
103 patients requiring complex subspecialty care. This system began administering T/C in
104 January 2022 to patients according to the patient prioritization scheme set forth by the
105 National Institute of Health’s COVID-19 Treatment Guidelines Panel.⁸ Patients initially
106 received 300mg of drug, but the FDA recommended an increased dose for a total of
107 600mg on February 24, 2022, based on *in vitro* studies using the Omicron variant.^{9 10 11}
108 Patients who had received the 300mg dose were advised to receive an additional
109 “catch-up” dose.

110 We reviewed the electronic medical records (EMR) of all patients who received T/C at
111 our institution between January 1, 2022 and July 31, 2022. Records were matched with
112 the health system’s COVID-19 testing data and with data on prescriptions for COVID-19
113 therapeutics including remdesivir (Veklury, Gilead), nirmatrelvir-ritonavir (Paxlovid,
114 Pfizer), and neutralizing monoclonal antibodies (including REGEN-COV
115 [casirivimab/imdevimab], sotrovimab, and bebtelovimab) from 10/01/2021 through
116 7/31/2022. Patients were considered to have had an episode of COVID-19 if they had a
117 positive SARS-CoV-2 test recorded in their EMR or if they had been prescribed one of
118 the therapeutic drugs between October 1, 2021, and July 31, 2022, through our health
119 system. Cases in which therapeutic drug was prescribed were verified by chart review

120 to ensure documentation confirming an active COVID-19 infection. We used EMR data
121 to obtain each patient’s demographic and medical characteristics including history
122 relevant to T/C eligibility, COVID immunization history, the clinical course of COVID-19
123 infection during the study period including whether infection resulted in hospitalization,
124 intensive care unit stay, or death, dates and doses of T/C receipt, date of first positive
125 COVID-19 test, and COVID-specific antiviral and monoclonal antibody therapeutics
126 received.

127 We used these data to describe the characteristics of those who developed COVID-19
128 before receiving T/C or after receiving T/C. For the latter group, we calculated the
129 interval between last dose of T/C and date of first positive test or prescription of COVID
130 therapeutic. For those patients with multiple positive tests, we performed chart review
131 to assess whether the repeat positive test was considered to have been consistent with
132 a new infection. We used chi square tests and Fishers exact p-values to examine the
133 difference between characteristics of those who got COVID before T/C and after T/C
134 prophylaxis.

135 To evaluate the temporal distribution of COVID-19 infections in those who did and did
136 not receive T/C prior to their illness, we plotted cases and hospitalizations by week of
137 diagnosis and T/C status. To place the cases in the context of the COVID-19 patterns
138 in the community and which variants were circulating in the San Diego area during the
139 same time interval, we used data from the SEARCH GitHub repository ([San Diego
140 Wastewater Surveillance - SEARCH \(searchcovid.info\)](#)) to develop a graph of mean
141 weekly wastewater concentrations of SARS-CoV-2 by variant type.

142 To examine the impact of T/C on rates of hospitalization, we calculated the proportion of
143 cases who required hospitalization among patients who received T/C before developing
144 COVID-19 and those who developed it after receiving T/C. We calculated rate ratios,
145 95% confidence intervals and two-tail Fischer exact p-value. For this analysis, we also
146 examined the rates by underlying condition (hematologic malignancy including bone
147 marrow transplantation, solid organ transplantation, and other, which included patients
148 with underlying immunosuppression such as rheumatologic conditions or advanced
149 AIDS).

150 This study was determined by the UC San Diego Institutional Review Board to be
151 exempt from Institutional Review Board requirements under categories 45 CFR
152 46.104(d), category 4.

153

154 **Results**

155 *General patient characteristics*

156 From January 1, 2022, through July 31, 2022, UC San Diego Health administered pre-
157 exposure T/C prophylaxis to 1295 unique patients, of whom approximately 9.2%
158 received it in January (the majority of which received “catch-up” doses in March), 18.8%
159 in February, 17.1% in March, 23.3% in April, 14.0% in May, and the remaining 17.6%
160 between June and July 2022.

161 The median age of the patients who received T/C was 59 years (range 18-99 years)
162 and 57.5% were male, 42.4% were female, and 0.1% were non-binary. A total of 37.2%

163 were solid organ transplant recipients, 47.7% had received bone marrow transplants or
164 had hematologic malignancies, and 15.1% had other qualifying conditions (including on
165 active chemotherapy, advanced HIV/AIDS, on significant immunosuppression for an
166 autoimmune disorder, etc).

167 *Characteristics of patients who developed COVID-19*

168 Of the 1295 T/C recipients, 223 met the COVID-19 case definition, of whom 121/223
169 (54.3%) became ill with COVID-19 before receiving T/C and 102/223 (45.7%)
170 developed breakthrough COVID-19 infection after receiving pre-exposure prophylaxis
171 (Table). A total of 168/223 (75.3%) were identified based on test results, and the
172 remaining 55/223 (24.7%) on the basis of having received COVID-19 therapy. The
173 median elapsed time to COVID-19 positivity was 80 days following T/C administration
174 (range 1 to 204 days).

175 The distribution of cases over time in our study cohort is shown in Figure 1A. Few cases
176 were identified between October and mid-December, after which there was a sharp
177 increase in cases coinciding with the rapid emergence of the Omicron variant (Figure
178 1C). The number of cases peaked in the first week of January, falling to a more
179 baseline level by the end of the month. All of the cases before and during the winter
180 peak were among patients who had not yet received T/C. Figure 1B demonstrates a
181 parallel rise in hospitalization during the winter peak, with all cases occurring among
182 those who had not yet received T/C. The local circulating strain was initially Omicron
183 BA.1, which was rapidly replaced by BA.1.1 (Figure 1C). In late April 2022, cases began

184 to rise again, with wastewater data showing increasing levels of Omicron BA2.12 and
185 subsequently BA.5.

186 We compared the 121 patients who developed COVID-19 prior to receiving T/C (pre-
187 T/C) with the 102 patients who developed it after receiving T/C (post T/C; Table). The
188 pre-T/C patients infected with COVID-19 were significantly younger than the post-T/C
189 patients infected with COVID-19 (median 54.5 years versus 60.5 years; Mann-Whitney
190 Wilcoxon two-sample test $p = 0.01$). Similar proportions of the pre-T/C and post-T/C
191 COVID-19 cases were male (54.6% versus 56.9%). Among the pre-T/C cases, 53/121
192 (43.8%) had hematologic malignancies or were bone marrow transplant recipients,
193 49/121 (40.5%) were solid organ transplant recipients, and the remaining 19/121
194 (15.7%) had other forms of immunosuppression. Among the post-T/C patients, 56/102
195 (54.9%) had hematologic malignancies or were bone marrow transplant recipients,
196 35/102 (34.3%) were solid organ transplant recipients, and 11/102 (10.8%) had other
197 forms of immunosuppression. The differences in distribution by gender and underlying
198 condition were not statistically significant.

199 Vaccine status and treatment with therapeutic agents also differed between pre-T/C and
200 post T/C COVID-19 cases. A higher proportion of the pre-T/C cases had not received
201 any doses of COVID-19 vaccine (15.7%, versus 3.0% for the post-T/C cases);
202 conversely the post-T/C cases were more likely to have received three or four doses
203 (72.2% versus 57.0%). The difference in number of doses was statistically significant (p
204 < 0.001). The majority (94/121; 77.7%) of the pre-T/C cases were treated with a
205 therapeutic agent, most commonly sotrovimab (56/121; 46.3%) and remdesivir (22/121;
206 18.2%), and 6/121 (5.0%) received nirmatrelvir-ritonavir, although the percentage of the

207 post-T/C receiving a therapeutic agent was significantly higher (91.2%; $p = 0.01$) than
208 the pre-T/C. In the post-T/C group, the most common therapeutic agents used included
209 nirmatrelvir-ritonavir (40/102; 39.2%), bebtelovimab (34/102; 33.3%), and remdesivir
210 (17/102; 16.7%).

211 *Hospitalization*

212 Thirty-six of the 121 (29.8%) patients who developed COVID-19 prior to receiving T/C
213 were hospitalized, with a median hospital length of stay of 8 days (range 1 to 119 days).
214 None of the patients died, though 8/121 (6.6%) required an intensive care unit stay. Two
215 patients underwent lung transplantation as a result of severe acute respiratory distress
216 syndrome due to COVID-19 and subsequently became eligible for, and received, T/C
217 after transplantation.

218 Six of 102 patients were hospitalized with COVID-19 after having received T/C (5.9%)
219 with a median hospital length of stay of 7 days (range 3 to 16 days). Four of the six
220 patients were solid organ transplant recipients, one patient had hematologic
221 malignancy, and one patient was on immunosuppressive therapy for an underlying
222 autoimmune disease. All of the hospitalized patients presented with symptoms
223 consistent with a viral respiratory infection including fever, cough, weakness, and
224 myalgia. Three of the hospitalized patients exhibited hypoxemia, and one of the patients
225 also had a *Legionella* co-infection. No patients in this population required an intensive
226 care unit stay or died.

227 The rate of hospitalization among those receiving T/C pre-exposure prophylaxis was
228 one-fifth the hospitalization rate of those who developed COVID-19 prior to receiving

229 T/C (rate ratio (RR) = 0.20; 95% confidence intervals (CI) = 0.09-0.45; $p < 0.001$). The
230 hospitalization rate for post-T/C patients with a hematologic malignancy or bone marrow
231 transplant who developed COVID-19 was less than one-tenth that of those who had not
232 yet received T/C (RR = 0.09; 95% CI = 0.01-0.64; $p = 0.002$). For patients who had
233 received solid organ transplants, the corresponding values were RR = 0.27; 95% CI =
234 0.10-0.71; $p = 0.003$; for patients with all other conditions, the RR was 0.43, with 95% CI
235 = 0.05-3.4; $p =$ not significant.

236 Discussion

237 We identified many COVID-19 cases among high-risk patients in our health system who
238 had received T/C for pre-exposure prophylaxis. However, when we compared those
239 who had contracted COVID-19 prior to receiving T/C prophylaxis with those infected
240 after, patients with infection after receiving T/C were significantly less likely to be
241 hospitalized for COVID-19.

242 Our findings differ from those of the initial clinical trial of T/C which had demonstrated an
243 83% reduced risk of symptomatic infection. However, that trial was conducted prior to
244 the emergence of Omicron, which has been the predominant circulating variant
245 worldwide since December 2021. Indeed, other monoclonal antibodies have been
246 shown to be ineffective against the Omicron variants.^{9 10 11} *In vitro* studies of
247 cilgavimab, one of the two components of T/C, suggested it would maintain some
248 efficacy against the emerging Omicron variants, but at a higher concentration than was
249 used in the PROVENT trial. In February 2022 the FDA recommended dose of T/C
250 should be doubled based on these predictions.

251 It is difficult to assess the impact of T/C prophylaxis on the low hospitalization rate in our
252 cohort. Almost all who had COVID-19 after receiving prophylactic T/C were also offered
253 additional treatment for symptomatic COVID-19, including updated monoclonal
254 antibodies or antivirals, and nearly three-quarters had received at least three COVID-19
255 vaccine doses, including 37% who had gotten four. In addition to the availability of
256 additional vaccine doses and a greater range of effective COVID-19 therapeutics over
257 time, there have also been rapidly changing subvariants of varying severity and
258 increasing immune evasiveness, further complicating the interpretation of therapeutic
259 effectiveness. Monoclonal antibodies targeting the regions of the spike protein of the
260 SARS CoV-2 virus under evolutionary pressure have not been able to be studied at a
261 pace that meets the speed of the evolution of variants in the COVID-19 pandemic.

262 Our study has several limitations. First, although we used multiple data sources to
263 identify cases, patients receiving COVID-19 care at other health care systems may not
264 have been captured in our data. Second, because the limitations imposed by the use of
265 administrative data, it was not possible to conduct a more rigorous analyses that might
266 have allowed us to determine the relative contributions of T/C, underlying patient
267 conditions, vaccine, circulating variants, and antiviral and monoclonal antibody
268 treatment to the risk of developing COVID-19. Finally, we did not have complete variant
269 data at the individual patient level to better assess risk of hospitalization by variant.

270 Despite these limitations, we believe our findings demonstrate that high-risk patients
271 who have received T/C are still developing symptomatic COVID-19 infections in the
272 Omicron era. Our results raise questions about the ongoing value of T/C pre-exposure
273 prophylaxis. This long-acting antibody combination requires significant resources for

274 administration to highly vulnerable patients. Given the many rapidly changing aspects of
275 the COVID-19 pandemic, including the evolution of variants and subvariants, the
276 protection offered by additional vaccine doses, and the development of effective
277 antivirals and therapeutic monoclonal antibodies, we are unable to truly assess the
278 contribution of T/C to the improved outcomes among patients over time without a
279 rigorous clinic trial. Such a trial, however, would be difficult to perform and would run the
280 risk of being rapidly outdated. As a result, decisions regarding the significant resources
281 required to administer this drug unfortunately continue to depend on data from *in vitro*
282 studies and expert recommendations.

283 **Acknowledgements:** We thank Shobha Kolan, Thomas Hatch, and Smruthi
284 Karthikeyan for their contributions to this study. We acknowledge the work performed
285 by the UC San Diego Health clinical team who provided tixagevimab/cilgavimab to
286 patients. No-one received compensation for their roles in this study.

287 **Author Contributions:** BC contributed to data curation, investigation, formal analysis,
288 writing and editing, NH contributed to data curation, formal analysis, writing, and editing,
289 NB contributed to investigation, formal analysis, writing, and editing, NL contributed to
290 methodology, project administration, writing, and editing, LH contributed to
291 methodology, project administration, writing, and editing, NY contributed to data
292 curation, methodology, project administration and editing, VC contributed to
293 investigation, project administration, and editing, and SRA contributed to
294 conceptualization, project administration, methodology, project administration, writing,
295 and editing.

296

297 **REFERENCES**

- 298
- 299 1. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of
300 mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the
301 United States: prospective observational study. *BMJ*. 03 09 2022;376:e069761.
 - 302 2. Malahe SRK, Hoek RAS, Dalm VASH, et al. Clinical characteristics and outcome of
303 immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective
304 observational study. *Clin Infect Dis*. Jul 23 2022;
 - 305 3. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab-
306 Cilgavimab) for Prevention of Covid-19. *N Engl J Med*. 06 09 2022;386(23):2188-2200.
 - 307 4. Stuver R, Shah GL, Korde NS, et al. Activity of AZD7442 (tixagevimab-cilgavimab)
308 against Omicron SARS-CoV-2 in patients with hematologic malignancies. *Cancer Cell*. 06 13
309 2022;40(6):590-591.
 - 310 5. Al Jurdi A, Morena L, Cote M, Bethea E, Azzi J, Riella LV. Tixagevimab/cilgavimab
311 pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid
312 organ transplant recipients during the omicron wave. *Am J Transplant*. Jun 21 2022;
 - 313 6. Nguyen Y, Flahault A, Chavarot N, et al. Pre-exposure prophylaxis with tixagevimab and
314 cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients.
315 *Clin Microbiol Infect*. Aug 01 2022;
 - 316 7. Benotmane I, Velay A, Gautier-Vargas G, et al. Breakthrough COVID-19 cases despite
317 prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant
318 recipients. *Am J Transplant*. Jun 17 2022;
 - 319 8. National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus
320 Disease 2019 (COVID-19) Treatment Guidelines.
321 <https://www.covid19treatmentguidelines.nih.gov/> Accessed August 25, 2022.
 - 322 9. Fiaschi L, Dragoni F, Schiaroli E, et al. Efficacy of Licensed Monoclonal Antibodies and
323 Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2. *Viruses*. 06 23
324 2022;14(7)
 - 325 10. VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529
326 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. *Nat Med*. 03
327 2022;28(3):490-495.
 - 328 11. Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to
329 widespread escape from neutralizing antibody responses. *Cell*. 02 03 2022;185(3):467-484.e15.
- 330

331 **Table:** Characteristics of recipients of tixagevimab-cilgavimab (T/C) who developed
 332 COVID-19 infection between October, 1 2021 and July 31, 2022

Patient Characteristic	Patients with COVID-19 infection prior to receipt of T/C (n = 121)	Patients with breakthrough COVID-19 infection following receipt of T/C (n = 102)	p-value
Median age [range], years	54.5 [18 – 79]	60.5 [25 – 99]	$p = 0.01$
Patient gender			
Male (%)	66 (54.5)	58 (56.9)	
Female (%)	55 (5.5)	44 (43.1)	
Underlying conditions			
Solid Organ Transplantation (%)	49 (40.5)	35 (34.3)	
Hematologic Malignancy (%)	37 (30.6)	28 (27.5)	
Bone Marrow Transplantation (%)	16 (13.2)	28 (27.5)	
Autoimmune (%)	9 (7.4)	3 (2.9)	
Neurologic (%)	4 (3.3)	3 (2.9)	
Solid Tumor Malignancy (%)	3 (2.5)	2 (2.0)	
HIV-AIDS (%)	3 (2.5)	2 (2.0)	
Other (%)	0 (0.0)	1 (1.0)	
Number (%) of vaccine doses received prior to COVID diagnosis[†]			
0	19 (15.7)	3 (3.0)	$p < 0.001$
1 – 2	33 (27.3)	25 (24.8)	
3	61 (50.4)	36 (35.6)	
4	8 (6.6)	37 (36.6)	
Therapeutics received (%)			
Nirmatrelvir-Ritonavir	6 (5.0)	40 (39.2)	$p = 0.01$
Bebtelovimab	0 (0.0)	34 (33.3)	
Remdesivir	22 (18.2)	17 (16.7)	
Sotrovimab	56 (46.3)	2 (2.0)	
Casirivimab-Imdevimab	10 (8.2)	0 (0.0)	
None	27 (22.3)	9 (8.8)	
Number of patients hospitalized (%)	36 (29.8)	6 (5.9)	$p < 0.001$
Number of patients with ICU stay (%)	8 (6.6)	0 (0.0)	$p = 0.01$
Hospital length of stay, days[‡] (%)			
1 – 7	17/36 (47.2)	3/5 (60.0)	
8 – 14	7/36 (19.4)	1/5 (20.0)	
15 – 30	3/36 (8.3)	1/5 (20.0)	
31 – 60	4/36 (11.1)	0 (0.0)	
≥ 61	5/36 (13.9)	0 (0.0)	
Number of deaths from COVID-19 (%)	0 (0.0)	0 (0.0)	

333

334 †One patient's vaccine history was not documented within the electronic medical record
335 ‡One patient was hospitalized at an outside institution and medical records were
336 unavailable to us

337

338

339 **Abbreviations:**

340 ICU = Intensive Care Unit

341 HIV-AIDS = Human Immunodeficiency Virus – Acquired Immunodeficiency

342

343 Figure 1A. Cases of COVID-19 by week and T/C status at the time of COVID-19
344 diagnosis, UC San Diego Health, October 2021 - July 2022

345

346 Figure 1B. Hospitalizations for COVID-19 by week and T/C status at the time of
347 COVID-19 diagnosis, UC San Diego Health, October 2021 - July 2022.

348 Figure 1C. Average weekly SARS CoV-2 wastewater viral loads/liter by variant, San
349 Diego County, October 2021 – July 2022.

350

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1A




Figure 1B




Figure 1C

